Baseus has this neat 5-in-1 charging station that, with Qi2 support, is a perfect accessory for Pixel 10 owners.

The dream of creating game-changing quantum computers—supermachines that encode information in single atoms rather than ...

For the Sony E-Mount, the 7Artisans lens will have a bit more competition, where there’s the similarly priced Viltrox AF 9mm ...

NEW YORK, Oct 24 (Reuters) - Snack maker Mondelez (MDLZ.O), opens new tab is using a new generative AI tool to cut costs for the production of marketing content by 30% to 50%, a senior executive told ...

Scammers like those charged in the NBA and Mafia poker ring seem willing to go to any extreme to fix games — even using ear pieces so tiny they need to be ripped out by a magnet, a cheating pro has ...

The Agriculture Department said that it would not use the funds to cover benefits in November, imperiling a program 42 million people use to pay for groceries. By Linda Qiu and Tony Romm Reporting ...

In my quest to find the best solution for Cake Wallet to offer user-friendly, non-custodial Lightning to our users, I’ve gone deep down the rabbit hole of both Spark and Ark. Both are quite novel ...

Listen to more stories on the Noa app. My tween-age daughters make me proud in countless ways, but I am still adjusting to the fact that they are not bookworms. I’m pretty sure that two generations ...

ChatGPT’s mobile app growth may have hit its peak, according to a new analysis of download trends and daily active users provided by the third-party app intelligence firm Apptopia. Its estimates ...

This current WNBA offseason is set up to be fascinating for several reasons. The most notable is the ongoing Collective Bargaining Agreement (CBA) negotiations between the league and the WNBA league ...

The Trump administration is reportedly considering making changes at the division of the IRS dedicated to conducting criminal investigations, The Wall Street Journal reported Wednesday, which could ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...